Use of Apatinib in Platinum-Resistant Epithelial Ovarian Cancer
Posted: Tuesday, August 25, 2020
For patients with platinum-resistant or platinum-refractory epithelial ovarian cancer, treatment with 250 mg/d of the small-molecular receptor tyrosine kinase inhibitor apatinib may be an alternative therapeutic option, according to the results of a single-center retrospective study published in Cancer Medicine. In addition, “our results suggest that taking low-dose apatinib is more acceptable especially in elderly patients without concession of efficacy,” reported Xiaohua Wu, PhD, of Fudan University Shanghai Cancer Center, China, and colleagues.
A total of 117 patients with platinum-resistant or platinum-refractory ovarian carcinoma were enrolled in the study. All patients were treated with 250 mg/d of apatinib. Using the Response Evaluation Criteria in Solid Tumors, version 1.1, tumor response and progression were assessed. In addition, the per-protocol analysis (n = 52) and the intention-to-treat analysis (n = 65) were used to assess patients.
Using the per-protocol analysis, the investigators found that 42.3% of patients had stable disease and 34.6% of patients had a partial response. There was also a 61.5% disease control rate. Moreover, the median progression-free survival and median overall survival were 4 months and 25 months, respectively. Furthermore, the intention-to-treat analysis revealed an objective response rate and a disease control rate of 27.7% and 49.2%, respectively. Patients older than 60 had prolonged progression-free survival and increased disease control rates.
Assessment of treatment-related adverse effects revealed that hypertension, hand-foot syndrome, and leukopenia were the top three events. A total of 15.4% of patients experienced grade 3 adverse events as defined by the per-protocol analysis. In addition, the efficacy of treatment with apatinib did not appear to be negatively impacted by previous adverse events, chemotherapy lines, or the number of recurrences.
Disclosure: For full disclosures of the study authors, visit onlinelibrary.wiley.com.
